Ron Wald


Scientist, Li Ka Shing Knowledge Institute

Tel: 416-867-3703
Twitter: @DrRonWald


Ron Wald is a nephrologist and Associate Professor of Medicine at the University of Toronto. A native of Montreal, he completed his undergraduate and medical degrees at McGill University and continued his clinical training in internal medicine and nephrology at the University of Toronto. Following this, he completed a Master in Public Health at Harvard University and a research fellowship at Tufts Medical Center in Boston. Since joining the St. Michael’s Hospital Division of Nephrology in 2006, Dr. Wald has been responsible for the hospital’s acute dialysis program. In addition to attending on the hospital’s Nephrology consult and ward services, he provides longitudinal care for patients on chronic hemodialysis and has an active general nephrology practice.

Dr. Wald’s research interests are in the areas of critical care nephrology and chronic dialysis. He is currently leading a Canadian Institutes of Health Research-funded international trial on the impact of the timing of dialysis initiation on survival in critically ill patients with acute kidney injury. He also has a strong interest in the long-term outcomes of patients who survive an episode of acute kidney injury and is co-leading a trial that is comparing specialized nephrology care vs usual care in this population. In the chronic dialysis area, Dr. Wald co-led a CIHR-funded study on the cardiovascular benefits of incentre nocturnal hemodialysis. He recently completed a multicentre pilot trial examining the implementation of two different levels of serum phosphate control in the hemodialysis population. A larger definitive trial to evaluate whether intensive serum phosphate lowering mediates improved clinical outcomes is planned. As a founding member of the Kidney Dialysis and Transplantation Program of the Institute for Clinical Evaluative Sciences, Dr. Wald is also involved in several studies that are using province-wide administrative data to answer research questions in kidney disease.

Recent Publications

  1. Massicotte-Azarniouch, D, Bader Eddeen, A, LazoLanger, A, Molnar, AO, Lam, NN, McCallum, MK et al.. Risk of Venous Thromboembolism in Patients by Albuminuria and Estimated GFR. Am. J. Kidney Dis. 2017; :. doi: 10.1053/j.ajkd.2017.07.003. PubMed PMID:28823585 .
  2. Keskar, V, McArthur, E, Wald, R, Harel, Z, Zimmerman, D, Molnar, A et al.. The Authors Reply. Kidney Int. 2017;92 (3):767. doi: 10.1016/j.kint.2017.06.006. PubMed PMID:28807268 .
  3. Acedillo, RR, Wald, R, McArthur, E, Nash, DM, Silver, SA, James, MT et al.. Characteristics and Outcomes of Patients Discharged Home from an Emergency Department with AKI. Clin J Am Soc Nephrol. 2017; :. doi: 10.2215/CJN.10431016. PubMed PMID:28729384 .
  4. Karbassi, A, Nair, K, Harris, L, Wald, RM, Roche, SL. Atrial tachyarrhythmia in adult congenital heart disease. World J Cardiol. 2017;9 (6):496-507. doi: 10.4330/wjc.v9.i6.496. PubMed PMID:28706585 PubMed Central PMC5491467.
  5. Molnar, AO, Eddeen, AB, Ducharme, R, Garg, AX, Harel, Z, McCallum, MK et al.. Association of Proteinuria and Incident Atrial Fibrillation in Patients With Intact and Reduced Kidney Function. J Am Heart Assoc. 2017;6 (7):. doi: 10.1161/JAHA.117.005685. PubMed PMID:28684642 .
  6. Dallaire, F, Wald, RM, Marelli, A. The Role of Cardiopulmonary Exercise Testing for Decision Making in Patients with Repaired Tetralogy of Fallot. Pediatr Cardiol. 2017;38 (6):1097-1105. doi: 10.1007/s00246-017-1656-z. PubMed PMID:28623384 .
  7. Abbott, BP, Abbott, R, Abbott, TD, Acernese, F, Ackley, K, Adams, C et al.. GW170104: Observation of a 50-Solar-Mass Binary Black Hole Coalescence at Redshift 0.2. Phys. Rev. Lett. 2017;118 (22):221101. doi: 10.1103/PhysRevLett.118.221101. PubMed PMID:28621973 .
  8. Unruh, WG, Wald, RM. Information loss. Rep Prog Phys. 2017;80 (9):092002. doi: 10.1088/1361-6633/aa778e. PubMed PMID:28585922 .
  9. Hanneman, K, Wald, R. Cardiac MRI T1 mapping in unrepaired anomalous left coronary artery from the pulmonary artery. Cardiol Young. 2017; :1-4. doi: 10.1017/S1047951117000932. PubMed PMID:28554340 .
  10. Wald, R, Rabbat, CG, Girard, L, Garg, AX, Tennankore, K, Tyrwhitt, J et al.. Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial. Clin J Am Soc Nephrol. 2017;12 (6):965-973. doi: 10.2215/CJN.10941016. PubMed PMID:28550080 PubMed Central PMC5460712.
Search PubMed

Affiliations & Other Activities

  • Nephrologist, St. Michael’s Hospital/University of Toronto
  • Associate Professor of Medicine, University of Toronto